The work with Regeneron is still relatively early. But it’s also focused in a number of bispecific strategies. We haven’t disclosed any specifics there, but the kinds of bispecifics, but of course they are very strong player in that field and we are absolutely delighted to be partnering with them, to be working with them and we expect really great things to come.
Lukas Shumway: Okay. Thank you.
Operator: Thank you. One moment for our next question. And our next question will come from line of Anupam Rama from JPMorgan. Your line is open.
Unidentified Analyst: Alright. Thank you for taking the question. This is actually Malcolm Kuno [ph] on for Anupam. Just one quick one, do you have a sense yet for which types of solid tumors you will be prioritizing for CX-904?
Sean McCarthy: Malcolm, could you repeat the first part of the question, we didn’t hear it clearly.
Unidentified Analyst: Oh, yes. Do you have a sense yet for which solid tumors we will be prioritizing for CX-904?
Sean McCarthy: Yes. Thanks for the question. Well, as I mentioned, in the early stages of the program, which we are in right now in Phase 1a, where we are escalating and exploring dosing schedule in the context of, broadly speaking, EGFR positive tumor types. So, as I put it, essentially a kind of EGFR positive all-comer strategy to gain initial experience with this drug candidate. As we move forward into Phase 1b next year, once we analyze the Phase 1a data, once we sit down with our partner Amgen, there are of course a multitude of EGFR positive tumors that we could move into, depending upon what we have seen in the early part of the clinical study. So, I think some of them are the obvious ones like lung, and head and neck name, but two, there could be others. And that will be a decision that will be taken. And we will take into consideration the commercial drivers of our partner, Amgen, so TBD.
Unidentified Analyst: Great. Thank you. Appreciate it.
Operator: Thank you. [Operator Instructions] Our next question will come from line of Peter Lawson from Barclays. Your line is open.
Courtney Bahlman: Good morning. This is Courtney on for Peter. Thank you for taking our question. I have a quick question on the CTLA program with BMS. What should we expect in the 2024 data update, and how many patients? Thank you.
Sean McCarthy: Well, thanks for the question. So, BMS most recently updated at their R&D Day, about a month ago. And the update was that they are with – this is with the non-fucosylated anti-CTLA-4 Probody that we call 288 that they are conducting proof-of-concept trials in non-small cell lung and MSF CRC, their studies are ongoing, the data are anticipated in 2024, but no additional details beyond that. So, we are keenly anticipating their data. And they of course are in the driver seat for data, disclosure and timing of any disclosures which at this point has not been clarified.
Courtney Bahlman: Thank you.
Sean McCarthy: You’re welcome.
Operator: Thank you. And I am not showing any further questions at this time. I would like to turn the conference back to Dr. Sean McCarthy for closing remarks.
Sean McCarthy: Great. Thanks very much and thanks everyone for your time today and for your interest in CytomX. This updates on our broad company progress has been helpful. Please feel free to reach out to our Investor Relations team should you have any questions and have a great rest of the day.
Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect. Everyone have a great day.
